Last reviewed · How we verify
Donepezil hydrochloride tablets
At a glance
| Generic name | Donepezil hydrochloride tablets |
|---|---|
| Sponsor | Wanbangde Pharmaceutical Group Co., LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (PHASE2)
- Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease (NA)
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Effect of Acetylcholinesterase Inhibitors on Bone Metabolism (PHASE2)
- Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type (PHASE2, PHASE3)
- Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) (PHASE1)
- Rivastigmine Mini-Tablet for Alzheimer's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: